Inhibition of production of anaphylatoxin C5a by eculizumab is another possible mechanism improving the glomerular function of PNH, as reported in cases of dense deposit disease and C3 glomerulonephritis [14]. The gene discussed is C5; the disease is C3 glomerulonephritis.